AgomAb Therapeutics (NASDAQ:AGMB) Director Buys 5,000 Shares of Stock

AgomAb Therapeutics NV (NASDAQ:AGMB) Director David Epstein acquired 5,000 shares of the company’s stock in a transaction on Thursday, October 8th. The shares were bought at an average price of $8.90 per share, with a total value of $44,500.00. Following the completion of the purchase, the director directly owned 15,000 shares of the company’s stock, valued at approximately $133,500. This represents a 50.00% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

AgomAb Therapeutics Stock Up 1.3%

Shares of NASDAQ:AGMB traded up $0.12 on Friday, hitting $9.34. The stock had a trading volume of 34,701 shares, compared to its average volume of 139,883. The firm’s 50 day moving average price is $12.68 and its 200-day moving average price is $11.95. AgomAb Therapeutics NV has a twelve month low of $7.97 and a twelve month high of $17.82.

AgomAb Therapeutics (NASDAQ:AGMB) last announced its quarterly earnings results on Thursday, August 6th. The company reported ($0.46) earnings per share (EPS) for the quarter. Equities research analysts predict that AgomAb Therapeutics NV will post -1.76 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

AGMB has been the topic of several research analyst reports. B. Riley Financial started coverage on shares of AgomAb Therapeutics in a research report on Thursday, July 23rd. They issued a “buy” rating and a $34.00 price objective on the stock. HC Wainwright reiterated a “buy” rating on shares of AgomAb Therapeutics in a research note on Wednesday, September 16th. Piper Sandler began coverage on shares of AgomAb Therapeutics in a report on Tuesday, August 25th. They issued an “overweight” rating and a $60.00 price target on the stock. Cantor Fitzgerald began coverage on shares of AgomAb Therapeutics in a research report on Wednesday, August 19th. They set an “overweight” rating for the company. Finally, Wall Street Zen cut AgomAb Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 27th. Seven analysts have rated the stock with a Buy rating and one has given a Hold rating to the company’s stock. According to MarketBeat, AgomAb Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $37.50.

AgomAb Therapeutics Company Profile

Agomab Therapeutics N.V. is a clinical-stage biotechnology company developing antibody-based medicines designed to activate biological pathways involved in tissue repair and regeneration. The company focuses on serious diseases in which restoring or rebuilding damaged tissue could provide therapeutic benefit.

Agomab’s lead program, AGMB-129, is an investigational, gut-restricted agonist of fibroblast growth factor receptor 1c (FGFR1c) being developed for inflammatory bowel disease, including Crohn’s disease.